Liquid Composition Comprising Vegf Antagonist
Patent No. EP3730126 (titled "Liquid Composition Comprising Vegf Antagonist") was filed by Samsung Bioepis on Dec 18, 2018. The application was issued on May 14, 2025.
Patent Summary
A stabilized liquid composition for protein drugs, particularly VEGF antagonists like aflibercept, comprising 5-100 mg/mL protein, 1-50 mM sodium phosphate buffer at pH 4-8, and 7.8-10% w/v stabilizer (trehalose or sucrose), without sodium chloride. The composition maintains protein stability and efficacy during extended storage through inhibition of polymerization, aggregation, and degradation.
Patent Family
Patent Oppositions (3)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3730126
- Application Number
- EP18893272A
- Filing Date
- Dec 18, 2018
- Status
- Granted And Under Opposition
- Apr 11, 2025
- Publication Date
- May 14, 2025
- External Links
- Slate, Register , Google Patents